Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...

Eli Lilly guided up to 2025 revenue of $58 to $61 billion, with analysts currently just above $58 billion. The guidance predicts sales growth of 32% for the year, and the management team actually ...

All told, Lilly stock still gained 33% in 2024, outperforming the S&P 500 and Nasdaq Composite. Unfortunately, Lilly ...

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good ...

The latest declines in Eli Lilly's stock price occurred in response to management's presentation at the annual JPMorgan ... The Motley Fool Stock Advisor analyst team just identified what they believe ...

(RTTNews) - Eli Lilly ... shareholders with Lilly holding a minority equity interest. The new company will be led by Dr. Friedman and members of the current Scorpion management team and will ...

Eli Lilly is experiencing explosive growth ... recent acquisition from Scorpion really drive home the point that Lilly's management is thinking much farther into the future, well beyond where ...

For the last couple of years, the pharmaceutical sector has become infatuated with glucagon-like peptide 1 (GLP-1) agonists used to treat diabetes and help with chronic weight management.